EUVIMEDEUVIMED entdecken
Crossref

Real‐World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients

Marilyne Daher iD, Fareed Khawaja iD, Amy Spallone iD, Terri L Shigle iD, Micah Bhatti iD, Nancy N Vuong iD, Ella J Ariza-Heredia iD, Victor Mulanovich iD, Richard E Champlin iD, Roy F Chemaly iD

Transplant Infectious Disease · 2025

DOI: 10.1111/tid.14444 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Infectious Disease, 2025. Verfasst von Marilyne Daher und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, Antiviral Agents, Hematologic Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Refractory and/or resistant (R/R) cytomegalovirus (CMV) infection is a serious complication after allogeneic hematopoietic cell transplantation (HCT). Maribavir, an oral antiviral agent, was approved in November 2021 for the treatment of R/R CMV in transplant recipients. However, real‐world data on the use of maribavir in HCT recipients and hematologic malignancy (HM) patients are limited. We described our early experience with the use of maribavir in the year after its Food and Drug Administration approval in HCT recipients and HM patients.

Methods

We performed a retrospective study of all patients who received maribavir for treatment of CMV infection at our center from November 2021 to December 2022. Clinical characteristics and outcomes of CMV infection were collected for each case. Descriptive statistics were calculated.

Results

Our study included 13 patients (11 of whom were HCT recipients and two with HM) who received a median of 58 days of maribavir therapy. While on maribavir, nine (69%) patients had a resolution of CMV infection. Treatment‐emergent maribavir resistance was documented in one patient with a CMV UL97 C480F mutation. Patients with higher baseline viral loads were less likely to achieve CMV resolution compared to those with lower levels. Additionally, six patients received combination therapy with maribavir. Six patients developed dysgeusia, none requiring maribavir discontinuation.

Conclusion

Maribavir is an effective and safe option for the treatment of R/R CMV infections in HCT recipients and HM patients. Our study highlights the complexities of managing CMV infections in this patient population and some challenges associated with maribavir therapy. image

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationAntiviral AgentsHematologic NeoplasmsRibonucleosidesBenzimidazolesHumansRetrospective StudiesFemaleMaleMiddle AgedAdultDrug Resistance, ViralCytomegalovirusAgedViral LoadTransplant RecipientsTreatment OutcomeDichlororibofuranosylbenzimidazole

Stichwörter der Autor:innen

CMV | hematopoietic cell transplantation | maribavir

Substanzen

maribavirAntiviral AgentsRibonucleosidesBenzimidazolesDichlororibofuranosylbenzimidazole

Autor:innen und Institutionen

  • Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Internal Medicine, Division of Infectious Diseases, Baylor College of Medicine, Houston, Texas, USA.
  • Division of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Stem Cell Transplantation & Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Marilyne Daher, Fareed Khawaja, Amy Spallone, Terri L Shigle, Micah Bhatti, Nancy N Vuong, Ella J Ariza-Heredia, Victor Mulanovich, Richard E Champlin, Roy F Chemaly

Zitieren

APA

Daher, M., Khawaja, F., Spallone, A., Shigle, T. L., Bhatti, M., Vuong, N. N., Ariza-Heredia, E. J., Mulanovich, V., Champlin, R. E., & Chemaly, R. F. (2025). Real‐World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients. Transplant Infectious Disease. https://doi.org/10.1111/tid.14444

Vancouver

Daher M, Khawaja F, Spallone A, Shigle TL, Bhatti M, Vuong NN, et al. Real‐World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients. Transplant Infectious Disease. 2025. doi:10.1111/tid.14444

BibTeX
@article{Daher2025,
  author = {Daher, Marilyne and Khawaja, Fareed and Spallone, Amy and Shigle, Terri L and Bhatti, Micah and Vuong, Nancy N and Ariza-Heredia, Ella J and Mulanovich, Victor and Champlin, Richard E and Chemaly, Roy F},
  title = {Real‐World Experience With Maribavir for Treatment of Refractory or Resistant Cytomegalovirus Infection in Hematopoietic Cell Transplant Recipients and Hematologic Malignancy Patients},
  journal = {Transplant Infectious Disease},
  year = {2025},
  doi = {10.1111/tid.14444}
}
Kostenlos starten →